Related Experiment Video
Updated: Jan 10, 2026
Disorders of Erythrocytes
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A Barbie1, Pablo Tamayo, Jesse S Boehm
1Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115 USA.
Abstract:
The proto-oncogene KRAS is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies. Although the identification of specific oncogenes has led to the development of clinically effective, molecularly targeted therapies in some cases, KRAS has remained refractory to this approach. A complementary strategy for targeting KRAS is to identify gene products that, when inhibited, result in cell death only in the presence of an oncogenic allele. Here we have used systematic RNA interference to detect synthetic lethal partners of oncogenic KRAS and found that the non-canonical IkappaB kinase TBK1 was selectively essential in cells that contain mutant KRAS. Suppression of TBK1 induced apoptosis specifically in human cancer cell lines that depend on oncogenic KRAS expression. In these cells, TBK1 activated NF-kappaB anti-apoptotic signals involving c-Rel and BCL-XL (also known as BCL2L1) that were essential for survival, providing mechanistic insights into this synthetic lethal interaction. These observations indicate that TBK1 and NF-kappaB signalling are essential in KRAS mutant tumours, and establish a general approach for the rational identification of co-dependent pathways in cancer.
Insights
Targeting the KRAS proto-oncogene in cancer is challenging. Researchers identified TBK1 as a synthetic lethal partner, meaning its inhibition kills cancer cells with KRAS mutations but spares normal cells.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The KRAS proto-oncogene is frequently mutated in aggressive human cancers, often leading to poor therapeutic responses.
- Targeting KRAS directly has proven difficult, necessitating alternative therapeutic strategies.
- Identifying synthetic lethal interactions offers a promising approach to selectively eliminate cancer cells harboring oncogenic mutations.
Purpose of the Study:
- To identify synthetic lethal partners of oncogenic KRAS using systematic RNA interference.
- To investigate the therapeutic potential of targeting identified synthetic lethal partners in KRAS-mutant cancers.
Main Methods:
- Systematic RNA interference (RNAi) screening was employed to identify genes synthetically lethal with oncogenic KRAS.
- The study focused on the non-canonical IkappaB kinase TBK1 as a potential synthetic lethal partner.
- Apoptosis induction and underlying signaling pathways (NF-kappaB, c-Rel, BCL-XL) were analyzed in KRAS-mutant cancer cell lines.
Main Results:
- TBK1 was identified as a gene selectively essential in cells with mutant KRAS.
- Suppression of TBK1 induced apoptosis specifically in human cancer cell lines dependent on oncogenic KRAS.
- TBK1 was found to activate NF-kappaB anti-apoptotic signals (c-Rel, BCL-XL) crucial for the survival of KRAS-mutant cancer cells.
Conclusions:
- TBK1 and NF-kappaB signaling pathways are essential for the survival of KRAS-mutant tumors.
- Targeting TBK1 represents a potential therapeutic strategy for KRAS-mutant cancers.
- This study establishes a framework for discovering co-dependent pathways in cancer through synthetic lethality screens.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:19Rh Blood Group
01:15Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
01:10Blood Typing
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...